PEXG (Cisplatin, Epirubicin, Capecitabine, Gemcitabine) Versus PDXG (Cisplatin, Docetaxel, Capecitabine, Gemcitabine) in Locally Advanced or Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial.

Trial Profile

PEXG (Cisplatin, Epirubicin, Capecitabine, Gemcitabine) Versus PDXG (Cisplatin, Docetaxel, Capecitabine, Gemcitabine) in Locally Advanced or Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2012

At a glance

  • Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary) ; Epirubicin (Primary) ; Gemcitabine (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms PACT-9
  • Most Recent Events

    • 31 Jan 2012 Actual end date Oct 2009 added as reported by ClinicalTrials.gov.
    • 31 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Oct 2009 Results have been reported at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top